drugset
drugset / Trial / NCT05536934

Arginase Inhibition in Humans With Obesity

NCT05536934 ↗

Phase 0 Completed 15 enrolled Karolinska Institutet
NaSingle-groupOpen-labelBasic science

Summary

To evaluate the efficacy of arginase inhibition on endothelial function in humans with obesity.

Timeline

Start
2016-12
Primary completion
2021-09
Completion
2022-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Nω-hydroxy-nor-arginine Unknown 0.1 mg Other

Indications

obesity disorder